MNG80
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.512
- PANCREAS_BETA_CELLS+0.448
- E2F_TARGETS+0.368
- SPERMATOGENESIS+0.329
- MYC_TARGETS_V1+0.230
- DNA_REPAIR+0.190
- OXIDATIVE_PHOSPHORYLATION+0.152
- G2M_CHECKPOINT+0.132
- MTORC1_SIGNALING+0.117
- INTERFERON_ALPHA_RESPONSE+0.109
Top 10 suppressed
- TGF_BETA_SIGNALING-0.433
- PROTEIN_SECRETION-0.420
- ANDROGEN_RESPONSE-0.390
- TNFA_SIGNALING_VIA_NFKB-0.390
- MITOTIC_SPINDLE-0.380
- APOPTOSIS-0.323
- HEME_METABOLISM-0.316
- HYPOXIA-0.300
- UV_RESPONSE_DN-0.293
- ESTROGEN_RESPONSE_EARLY-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OR-A5JJ-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.810 |
| 2 | TCGA-BA-6871-01A-11R-1873-07 | — | — | 0.806 |
| 3 | TCGA-HN-A2NL-01A-11R-A18M-07 | — | E | 0.805 |
| 4 | SRR1516061 | — | — | 0.782 |
| 5 | MBCProject_3717_T3_RNA | — | B | 0.780 |
| 6 | SRR25617852 | — | B | 0.779 |
| 7 | R175 | — | — | 0.775 |
| 8 | TCGA-AO-A1KR-01A-12R-A144-07 | — | E | 0.769 |
| 9 | SRR25617851 | — | B | 0.767 |
| 10 | 412859bb-8b2a-44bf-b3b2-6acd30986067 | — | — | 0.766 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.512 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.448 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.368 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.329 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.152 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.132 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.117 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.109 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.076 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.057 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.049 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.039 | Inavolisib | — uncovered |